BioCentury Podcasts

•

Chaîne • 2 émissions

Science de la vie

Science de la vie

Toutes les 2 semaines
Science de la vie

Science de la vie

Chaque semaine

02/06/2021

Ep. 60 - D-Day for Aducanumab: What's at stake

Reach us by sending a text

02/06/2021

•

15 min
07/11/2023

Ep. 202 - A DMD Decision & Endpoint Innovation

The controversy around Sarepta continues as the company’s executives were confident last week that the data from the Phase III EMBARK trial of Duchenne muscular dystrophy gene therapy Elevidys were enough to warrant full approval despite missing the study’s primary endpoint. On the latest BioCentury This Week podcast, BioCentury’s editors analyze the pitfalls facing FDA as the agency considers whether to apply regulatory flexibility in its decision-making and the impact its decision could have for patients and future therapies that are submitted to the agency with less than clear-cut positive data. The editors also discuss innovations around new endpoints and technologies for clinical trials and the tepid reception for the latest biotech IPO, the debut by Lexeo. Reach us by sending a text

07/11/2023

•

30 min
06/12/2022

Ep. 151 - Alzheimer's Takeaways, U.K. Biotech, Charles Forum

CTAD data for lecanemab showed more definitively than any past readout that targeting β-amyloid can lead to clinical benefit for Alzheimer’s patients, but the field is still wrestling with its use as a surrogate endpoint, BioCentury Executive Editor Selina Koch said on the latest BioCentury This Week podcast. Koch and the BioCentury podcast team break down the implications of data from Eisai and Roche at last week’s Clinical Trials on Alzheimer’s Disease meeting and look ahead to what’s next for the field. BioCentury’s editors also discussed how proposed changes to the U.K.’s R&D tax credit scheme could hurt British biotechs and what regulatory heads of global biopharmas who are members of the Charles Forum are envisioning for the post-COVID regulatory environment. Reach us by sending a text

06/12/2022

•

27 min
22/08/2025

Ep. 91 – Annalisa Jenkins: How MHRA’s Reset Could Revive U.K. Biotech

A new head at MHRA, a streamlined government life sciences strategy, and a more sophisticated innovation ecosystem have Annalisa Jenkins optimistic about the future of U.K. biotech — and its potential to carve out a stronger global role. On The BioCentury Show, Annalisa Jenkins, chair of Gemma Biotherapeutics, discussed the evolving landscape of biotech in the U.K. and the critical hurdles it faces as it implements the latest strategy. Jenkins, who was president and CEO of Dimension Therapeutics, is a committee member on the Science Board to FDA, a board member of Genomics England and Faster Cures, and chair of the court at the London School of Hygiene and Tropical Medicine. View full story: https://www.biocentury.com/article/656787 #UKBiotech #MHRA #BiotechStrategy #GrowthCapital #RegulatoryScience #TalentAttraction 00:00 - Introduction 02:52 - State of U.K. Biotech 13:15 - Improving U.K.’s Path to Clinic 18:50 - What’s Next for MHRA 24:53 - Changes at FDA 29:58 - Working with China

22/08/2025

•

36 min
09/05/2023

Ep. 175 - Acelyrin IPO, Alzheimer's Data & Digital Endpoints

Acelyrin last week parlayed a late-stage asset for hidradenitis suppurativa and veteran leadership into one of biotech’s largest-ever NASDAQ IPOs. On the latest BioCentury This Week podcast, BioCentury’s editors discussed how Acelyrin generated outsized demand for its offering and assessed Alzheimer’s data for Eli Lilly's donanemab, the promise and challenges of digital endpoints and takeaways from the latest BioCentury Show, which featured incoming FogPharma CEO Mathai Mammen in conversation with Editor in Chief Simone Fishburn. This week’s podcast is sponsored by Cancer Research Horizons. Reach us by sending a text

09/05/2023

•

25 min
13/06/2024

Ep. 62 - Rick Bright: Navigating the Avian Flu Threat

The U.S. is experiencing events that are either the first stages of a widespread avian influenza outbreak or a fire drill that will show how well the nation is prepared for an outbreak. The U.S. has not stepped up to meet the challenge, Rick Bright, the former director of BARDA, told BioCentury. In an interview with The BioCentury Show's Steve Usdin, Bright said there are opportunities for biotech companies to help fill voids in surveillance, point-of-care diagnostics, vaccines and therapeutics. The federal government must provide leadership and funding to unleash industry, but it has acted slowly and hasn’t taken the necessary initiative, Bright said. View full story: https://www.biocentury.com/article/652676 #biotech #biopharma #pharma #lifescience #politics #policy #law 00:00 - Intro 01:56 - H5N1: State of Play 10:14 - Rebuilding Trust, Vaccines 20:50 - Creating Better Therapeutics 25:34 - BARDA, Barriers to Preparedness 32:50 – Urgent Next Steps

13/06/2024

•

40 min
22/08/2024

Popular Episode - Bob Nelsen on AI, China and the IRA

This is a previously recorded episode of The BioCentury Show from February 22, 2024. Subscribe to this channel to listen to each new episode. Visit TheBioCenturyYouTube.com to access and watch all prior episodes. In a wide-ranging conversation with BioCentury, Bob Nelsen, co-founder and managing director of Arch Venture Partners, said he is excited by the potential for AI to “create a language of biology,” is cautious about investing in China given increasing geopolitical tensions, and is convinced that the U.S. healthcare system could do a far better job of delivering on the promise of rapidly progressing science. Nelsen, who has helped finance and create more than 150 companies, including 47 that have reached valuations exceeding $1 billion, discussed his conviction that focusing on creating transformational medicines, rather than looking for short-term gains, is a key to success in the life sciences. View full story: https://www.biocentury.com/article/651502 #biotech #pharma #biopharma #TheBioCenturyShow 0:00 - Introduction 01:59 - The Promise of AI 08:35 - The Inflation Reduction Act 15:38 - China 25:58 - Building Companies Around Big challenges

22/08/2024

•

36 min
11/01/2022

Ep. 97 - Buysiders' Picks, plus JPM22 roundup

Reach us by sending a text

11/01/2022

•

28 min
25/09/2025

Ep. 323 - Agentic AI: From New Targets to the Clinic

AI is bringing sweeping changes to drug development, from how targets are discovered to optimizing clinical trials to maximize an asset’s chance for success. On a special edition of the BioCentury This Week podcast, IQVIA’s Greg Lever joins BioCentury’s analysts to discuss agentic AI’s short- and long-term prospects to help biotechs discover new targets, predict success in preclinical development, and enhance clinical operations. This episode of BioCentury This Week is sponsored by IQVIA Biotech. View full story: https://www.biocentury.com/article/657086 #Biotech #Biopharma #DrugDevelopment #ClinicalTrials #TargetDiscovery #AgenticAI #GraphRAG #DeRisking 00:01 - Sponsor Message: IQVIA Biotech 01:22 - AI in Biotech 05:01 - Machine Learning 06:21 - Generative AI and Language Models 08:37 - Agentic AI 12:43 - AI in Target Discovery 23:44 - AI in Clinical Trial Design To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

25/09/2025

•

29 min
17/03/2023

Ep. 166 - SVB Shakeout: Next Steps for Biotech

On a special edition of the BioCentury This Week podcast, Editor in Chief Simone Fishburn and Director of Biopharma Intelligence Stephen Hansen assess the priorities for VCs and their portfolio companies in the immediate aftermath of the collapse of Silicon Valley Bank. They also discuss the gap left in the biotech ecosystem given SVB’s unique relationship with VCs and small companies, and what the knock-on effects may be on the sector as it continues to grapple with the bear market. Reach us by sending a text

17/03/2023

•

24 min

BioCentury Podcasts leverage three decades of biopharma intelligence with thoughtful, accurate, and objective insights. BioCentury editors spotlight key scientific opinion leaders, corporate decision-makers, venture capitalists, and patient advocates, keeping you informed on the most current biotech stories and highlighting life science innovations.

Site web

BioCentury Podcasts

Meilleures émissions

Ep. 60 - D-Day for Aducanumab: What's at stake

Ep. 202 - A DMD Decision & Endpoint Innovation

Ep. 151 - Alzheimer's Takeaways, U.K. Biotech, Charles Forum

Ep. 91 – Annalisa Jenkins: How MHRA’s Reset Could Revive U.K. Biotech

Ep. 175 - Acelyrin IPO, Alzheimer's Data & Digital Endpoints

Ep. 62 - Rick Bright: Navigating the Avian Flu Threat

Popular Episode - Bob Nelsen on AI, China and the IRA

Ep. 97 - Buysiders' Picks, plus JPM22 roundup

Ep. 323 - Agentic AI: From New Targets to the Clinic

Ep. 166 - SVB Shakeout: Next Steps for Biotech

À propos

BioCentury Podcasts

Meilleures émissions

Meilleurs épisodes

À propos